Bioequivalence To Duopa Could Mean Quick Path To Market For NeuroDerm In Parkinson’s
This article was originally published in The Pink Sheet Daily
With several companies working on new Parkinson’s therapies to maintain therapeutic levels of levodopa, NeuroDerm thinks it has a formulation that will offer similar benefits to AbbVie’s Duopa, with less invasive therapy.
You may also be interested in...
NeuroDerm Ltd. reported Phase II results for its drug-device combination product ND0612 that reinforce its ability to fill a gap in the treatment of advanced Parkinson's disease, and it could be on the market in the US in less than three years if the company is able to stay on its revised development path.
EU Regulatory Round-Up, February 2020: Brexit And Swixit Threaten Huge Disruption Amidst MDR Uncertainty
Complying with the EU’s new Medical Device Regulation would be hard enough. But more layers of uncertainty – especially Brexit and Swixit ̶ mean European medtech is navigating very turbulent waters right now.
Fresenius Kabi has reported sales ahead by 6% in 2019, as growth in emerging markets helped to offset a subdued increase in North America. Meanwhile, the firm has pushed back financial expectations for its biosimilars by a year.